Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...
Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...
The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...
Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback